Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...
Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...
Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...
MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...
27 ม.ค. 2568 - 13:56 น. น้าโย่ง เชิญยิ้ม อัพเดตอาการหลังผ่าตัด หมอนรองกระดูกสันหลังครั้งที่ 2 ตอนนี้ดี ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback